Compass Pathways bring forward the likely commercial launch of their synthetic psilocybin, COMP360, for treatment-resistant depression by 9 to 12 months.

The British company Compass Pathways have just announced that they hope to bring forward the commercial launch of their synthetic psilocybin - COMP360 - used for treatment-resistant depression by 9 to 12 months. Kabir Nath, their Chief Executive Officer, said “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 months. We are accelerating commercial launch plans to match this new expected timeline with the goal of advancing our mission of transforming the mental health landscape and how patients living with depression are treated.” The Company now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026. Disclosure of 26-week (Part B) COMP006 data is expected in early Q3 2026. This suggests potential US FDA approval could occur in 2027.

For more psychedelic news and research, visit the psychedelic health professional network homepage.